Researchers at AACR discussed what's next for the drug class, given the disappointing activity of tiragolumab with Tecentriq ...

The nonprofit says its pipeline offers more affordable and accessible therapeutics, including point-of-care CAR-T cell therapy for leukemia and lymphoma.

The firm enrolled the first patient at Florida's BayCare Morton Plant Hospital, and the study procedure went according to protocol, per an investigator.

The firm is expecting Phase III readouts this year for its FGFR2b drug bemarituzumab and is advancing a second KRAS inhibitor to the clinic.

DCx will gain rights to technology, targets, and preclinical programs from Repare along with lab space and staff in Montreal.

The companies will analyze RNA sequencing data from Scipher to identify biomarkers for patient stratification and drug development.

The clinical trial will include nearly 150 patients with advanced hepatocellular carcinoma that expresses glypican-3.

A trial by MSK researchers has shown that neoadjuvant treatment with GSK's Jemperli spared 80 percent of patients with dMMR ...

The company said it took financial hits from the Inflation Reduction Act's Medicare Part D redesign, which included higher ...

Most adults in the US would take a blood test to assess whether they will develop Alzheimer's, according to the survey, ...

When patients with solid tumors had the same liquid- and tissue-based test findings, patients had better outcomes on molecular tumor board-guided therapy.